Sone-Ve: Gastric Cancer Survival
AstraZeneca's Sone-Ve Shows Significant Survival Benefit in Advanced Gastric Cancer Phase III
Anonymous
Key Points
1
Sone-Ve was well tolerated with no new safety signals reported in CLARITY-Gastric01.
2
Regulatory potential includes Orphan Drug and Breakthrough designations in major markets, and AstraZeneca plans to validate a companion diagnostic assay to identify CLDN18.2-positive patients.
3
The CLARITY-Gastric01 trial employed a dose-selection Stage 1 with two Sone-Ve dose arms (2.2 mg/kg or 1.8 mg/kg every three weeks) and Stage 2 continued with 2.2 mg/kg.
4
Beyond gastric and GEJ cancers, the trial also included oesophageal adenocarcinoma (EAC) patients with CLDN18.2 expression, expanding the potential eligible population.
5
CLARITY-Gastric01 is the first Phase III trial to demonstrate an OS benefit with an anti-CLDN18.2 ADC in this setting.
AstraZeneca's antibody-drug conjugate sonesitatug vedotin — known as Sone-Ve — has shown a statistically significant and clinically meaningful overall survival benefit in patients with CLDN18.2-positive advanced gastric and gastroesophageal junction cancers. The results come from the CLARITY-Gastric01 Phase III trial, targeting patients in the 2nd line of treatment and beyond, according to MarketScreener.
The trial met both of its dual primary endpoints: overall survival in the 3rd-line-plus setting and overall survival in the broader 2nd-line-plus population. Barchart reported that CLARITY-Gastric01 is the first Phase III trial to show an OS benefit with any anti-CLDN18.2 ADC in this setting — a milestone that could reshape how gastric cancer is treated worldwide.
What CLDN18.2 Is and Why It Matters
Claudin 18.2, or CLDN18.2, is a protein found on the surface of certain cancer cells. It is expressed in roughly 60% of gastric and GEJ cancers when at least 25% of tumor cells carry the marker, according to MarketScreener. That makes it one of the larger targetable patient populations in GI oncology.
Sone-Ve is an antibody-drug conjugate, or ADC. Think of it as a guided missile: an antibody locks onto CLDN18.2 on the cancer cell, then delivers a toxic payload directly inside it. This approach aims to kill cancer cells while sparing healthy tissue. The therapy is positioned as a potential first-in-class CLDN18.2-targeted ADC, according to Financial Content.
How the CLARITY-Gastric01 Trial Was Designed
The trial ran in two stages. Stage 1 tested two doses of Sone-Ve: 2.2 mg/kg or 1.8 mg/kg given every three weeks. Stage 2 moved forward with the higher 2.2 mg/kg dose. The trial enrolled patients with advanced gastric cancer, GEJ cancer, and also oesophageal adenocarcinoma — a cancer of the lower esophagus — if they showed CLDN18.2 expression, per MarketScreener.
The trial also tracked progression-free survival, or PFS — how long patients lived without their cancer getting worse. Results showed a trend toward improved PFS, but that finding did not reach statistical significance. No new safety signals were reported, and Sone-Ve was described as well tolerated, according to Barchart.
Regulatory Designations Signal High Confidence in Sone-Ve
Sone-Ve already holds Orphan Drug and Breakthrough Therapy designations in major markets. These labels are granted to drugs that target rare or serious diseases and show early signs of strong benefit. They can speed up the review process once companies submit data to regulators, according to Financial Content.
AstraZeneca also plans to develop and validate a companion diagnostic test. This test would identify which patients have CLDN18.2-positive tumors — and are therefore eligible for treatment. The company wants to expand what counts as CLDN18.2 positivity, potentially bringing more patients into the eligible pool, per MarketScreener.
AstraZeneca Bets Big on GI Cancer Franchise
These results are part of a broader AstraZeneca push to build a GI cancer business around targeted and immune-based drugs. Sone-Ve is being studied across multiple GI tumor types and across different lines of therapy — not just after two prior treatments. The CLARITY-Gastric01 data are expected to form the basis of a regulatory submission, according to Barchart.
If approved, Sone-Ve could reduce reliance on standard chemotherapy for patients who have already failed at least one prior treatment. Gastric cancer is one of the leading causes of cancer death globally. A first-in-class targeted ADC in this space would mark a significant step forward for a disease with few good options after first-line therapy, per Financial Content.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
10
Articles
37
Reach
47
A
AnonymousAuthor
